XBiotech to Begin Constructing New R&D Facility on Its 48-acre Campus
XBiotech to Begin Constructing New R&D Facility on Its 48-acre Campus
The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate wet laboratories, especially to enable ongoing infectious disease programs. In keeping with XBiotech's desire to preserve the woodlands nature on the 48 acre campus, a subterranean parking garage is being constructed to minimize footprint and ecological impact of the new structure.
Architectural Rendition of XBiotech's Planned R&D Facility
xBiotech計劃研發設施的建築再現
Architectural Rendition of XBiotech's Planned R&D Facility
xBiotech計劃研發設施的建築再現
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024.
得克薩斯州奧斯汀，2024年1月4日（GLOBE NEWSWIRE）——xBiotech Inc.今天宣佈，計劃通過建造一座新的、最先進的研發設施來擴建其園區總部。xBiotech已獲得奧斯汀市的批准，可以開始挖掘以進行場地準備，基礎工作預計將開始 1st 2024 年季度。
The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate wet laboratories, especially to enable ongoing infectious disease programs. In keeping with XBiotech's desire to preserve the woodlands nature on the 48 acre campus, a subterranean parking garage is being constructed to minimize footprint and ecological impact of the new structure.
這座新的四層樓建築將位於現有的46,000英尺附近2 製造和研發設施，將提供關鍵基礎設施，以支持該公司Natrunix風溼病學計劃的商業化計劃。全新 46,000 英尺以上2 該設施將容納臨床和醫療業務、商業化團隊，甚至包括溼式實驗室，特別是爲了支持正在進行的傳染病項目。爲了滿足xBiotech在佔地48英畝的校園中保護林地自然的願望，正在建造一個地下停車場，以最大限度地減少新建築的佔地面積和生態影響。
John Simard, President and CEO of XBiotech commented, "We are excited to begin construction of what will be a unique and remarkable R&D facility. It will add significant operational capability to our existing manufacturing and R&D operations on the campus, and will create among the most capable biotechnology operations in Texas."
xBiotech總裁兼首席執行官約翰·西瑪德評論說：“我們很高興開始建造一個獨特而卓越的研發設施。它將爲我們在園區內現有的製造和研發業務增加顯著的運營能力，並將成爲德克薩斯州最有能力的生物技術企業之一。”
About XBiotech
XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human technology. The company's mission is to rethink the way antibody medicines are discovered and commercialized by advancing its robust pipeline of truly natural human antibodies for treating serious diseases such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. XBiotech has several candidate products including Natrunix. Cloned from individual donors who possess natural immunity against certain targeted diseases, XBiotech's pipeline of True Human antibodies are intended to deliver unmatched safety and efficacy. Located just minutes from downtown Austin, the XBiotech campus headquarters includes GMP manufacturing facilities, research and testing laboratories, infectious disease research facilities, and quality control and clinical operations. For more information, visit www.xbiotech.com.
關於 xBiotech
xBiotech在基於其真人技術的基礎上率先發現和開發靶向抗體。該公司的使命是通過推進其強大的產品線，重新思考抗體藥物的發現和商業化的方式 真的 天然的人體抗體，用於治療嚴重疾病，例如風溼病、傳染病、心血管疾病和癌症等炎症性疾病。xBiotech有幾種候選產品，包括Natrunix。xBiotech的True Human抗體產品線從對某些靶向疾病具有自然免疫力的個人捐贈者中克隆而來，旨在提供無與倫比的安全性和有效性。xBiotech園區總部距奧斯汀市中心僅數分鐘路程，包括GMP製造設施、研究和測試實驗室、傳染病研究設施以及質量控制和臨床運營。欲了解更多信息，請訪問 www.xbiotech.com。
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
關於前瞻性陳述的警示說明
本新聞稿包含前瞻性陳述，包括有關管理層信念和期望的聲明，這些聲明涉及重大風險和不確定性。前瞻性陳述在預測未來業績和條件時存在固有的風險和不確定性，這些風險和不確定性可能導致實際結果與這些前瞻性陳述中的預測存在重大差異。這些風險和不確定性受我們在美國證券交易委員會某些文件的 “風險因素” 部分中披露的約束。我們在本新聞稿中所作的任何前瞻性陳述僅代表截至本新聞稿發佈之日。在本新聞稿發佈之日之後，無論是由於新信息、未來事件還是其他原因，我們都沒有義務更新我們的前瞻性陳述。
Contact
聯繫我們
Wenyi Wei
wwei@xbiotech.com
Tel. 737-207-4600
魏文義
wwei@xbiotech.com
電話：737-207-4600
Photos accompanying this announcement are available at
本公告附帶的照片可在以下網址獲得
譯文內容由第三人軟體翻譯。
